5,000 Shares in Becton, Dickinson and Company (BDX) Purchased by Canal Insurance CO

Canal Insurance CO purchased a new position in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 5,000 shares of the medical instruments supplier’s stock, valued at approximately $976,000.

Several other large investors also recently modified their holdings of BDX. Waldron LP acquired a new stake in shares of Becton, Dickinson and in the 1st quarter worth approximately $383,000. Quadrant Capital Management LLC lifted its stake in shares of Becton, Dickinson and by 0.5% in the 1st quarter. Quadrant Capital Management LLC now owns 19,825 shares of the medical instruments supplier’s stock worth $3,637,000 after acquiring an additional 105 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Becton, Dickinson and in the 1st quarter worth approximately $2,280,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Becton, Dickinson and by 2.5% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 37,268 shares of the medical instruments supplier’s stock worth $6,836,000 after acquiring an additional 903 shares during the period. Finally, Geneva Advisors LLC lifted its stake in shares of Becton, Dickinson and by 0.8% in the 1st quarter. Geneva Advisors LLC now owns 392,781 shares of the medical instruments supplier’s stock worth $72,052,000 after acquiring an additional 3,192 shares during the period. 87.12% of the stock is owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 195.61 on Tuesday. The company’s 50 day moving average is $199.25 and its 200 day moving average is $191.52. The company has a market capitalization of $44.51 billion, a P/E ratio of 56.65 and a beta of 1.06. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period last year, the company earned $2.35 earnings per share. The firm’s revenue was down 5.1% compared to the same quarter last year. Analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.49%. Becton, Dickinson and’s payout ratio is 83.43%.

COPYRIGHT VIOLATION NOTICE: “5,000 Shares in Becton, Dickinson and Company (BDX) Purchased by Canal Insurance CO” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://stocknewstimes.com/2017/09/19/5000-shares-in-becton-dickinson-and-company-bdx-purchased-by-canal-insurance-co.html.

A number of analysts have recently weighed in on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company reissued a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a research note on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and set a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $196.93.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by corporate insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply